BridgePort Financial Solutions LLC Acquires Shares of 8,318 GSK plc (NYSE:GSK)

BridgePort Financial Solutions LLC bought a new stake in shares of GSK plc (NYSE:GSK - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 8,318 shares of the pharmaceutical company's stock, valued at approximately $310,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Dodge & Cox raised its position in shares of GSK by 0.5% in the fourth quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock valued at $2,314,672,000 after buying an additional 353,749 shares during the last quarter. FMR LLC increased its position in GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA increased its position in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after purchasing an additional 10,407,905 shares during the last quarter. Fisher Asset Management LLC increased its position in GSK by 1.4% during the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock worth $637,061,000 after purchasing an additional 259,867 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in GSK by 0.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock worth $255,914,000 after purchasing an additional 35,134 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on GSK shares. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas started coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Stock Up 2.6%

Shares of GSK stock traded up $1.03 on Friday, hitting $41.03. The stock had a trading volume of 7,371,682 shares, compared to its average volume of 4,859,081. The firm has a market capitalization of $84.65 billion, a price-to-earnings ratio of 25.81, a P/E/G ratio of 1.12 and a beta of 0.51. The stock's 50 day moving average is $37.29 and its 200-day moving average is $36.11. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.01.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. As a group, research analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.11%. GSK's dividend payout ratio is 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.